As previously discussed in our report, “Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies,” 210 federal securities class actions were filed in 2021, a 34% drop from the 319 filings in 2020...more
5/2/2022
/ Acquisition Agreements ,
Class Action ,
D&O Insurance ,
Delaware General Corporation Law ,
Derivative Suit ,
Disclosure Requirements ,
Duty of Care ,
Merger Agreements ,
Misleading Statements ,
Regulatory Agenda ,
Rulemaking Process ,
Securities Fraud ,
Securities Litigation ,
Special Purpose Acquisition Companies (SPACs)